tiprankstipranks
Company Announcements

Enanta Pharmaceuticals Stockholders Approve Key Proposals in 2025

Story Highlights
  • Enanta Pharmaceuticals re-elected two directors and increased shares in the equity plan.
  • Stockholders approved annual advisory votes on executive pay and ratified the auditor.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Enanta Pharmaceuticals Stockholders Approve Key Proposals in 2025

An announcement from Enanta Pharmaceuticals ( (ENTA) ) is now available.

At the Annual Meeting on March 13, 2025, Enanta Pharmaceuticals’ stockholders voted on several key proposals. They re-elected two Class III directors, approved an amendment to the 2019 Equity Incentive Plan to increase shares by 800,000, decided to hold an annual advisory vote on executive compensation, approved the executive compensation, and ratified PricewaterhouseCoopers LLP as the independent auditor for the 2025 fiscal year.

More about Enanta Pharmaceuticals

YTD Price Performance: 18.96%

Average Trading Volume: 540,995

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $141.9M

See more data about ENTA stock on TipRanks’ Stock Analysis page.

Questions or Comments about the article? Write to editor@tipranks.com

Questions or Comments about the article? Write to editor@tipranks.com
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App